Русская версия English version   
О журнале
Редакционная коллегия
Правила для авторов
Информация для читателей и авторов
Оглавление текущего номера
Архив
Контакты
Поиск

Отправить статью
 


Том 20   Выпуск 2   Год 2025
Список литературы

  1. UNAIDS. Global HIV and AIDS Statistics. 2023. https://www.unaids.org/en/resources/fact-sheet (accessed 03.07.2025).
  2. Han S., Lu Y. Fluorine in anti-HIV drugs approved by FDA from 1981 to 2023. Eur. J. Med. Chem. 2023. doi: 10.1016/j.ejmech.2023.115586
  3. Smyth R.P., Davenport M.P., Mak J. The origin of genetic diversity in HIV-1. Virus Res. 2012;169(2):415-429. doi: 10.1016/j.virusres.2012.06.015
  4. Smith R.J., Wahl L. Distinct effects of protease and reverse transcriptase inhibition in an immunological model of HIV-1 infection with impulsive drug effects. Bull. Math. Biol. 2004;66:1259-1283. doi: 10.1016/j.bulm.2003.12.004
  5. Lou J., Smith R.J. Modelling the effects of adherence to the HIV fusion inhibitor enfuvirtide. J. Theor. Biol. 2011;268(1):1-13. doi: 10.1016/j.jtbi.2010.09.039
  6. Chowdhury S., Roy P.K., Smith R.J. Mathematical modelling of enfuvirtide and protease inhibitors as combination therapy for HIV. Int. J. Nonlinear Sci. Numer. Simul. 2016;17(6):259-275. doi: 10.1515/ijnsns-2015-0051
  7. Ghosh T., Schwartz E.J., Ghosh S., Roy P.K. Mathematical overview of biochemical and physical interactions considering reverse transcriptase and integrase enzymes to explore HIV progression: A control theoretic approach. In: Int. Conf. on Math. Analysis and Application in Modeling. Springer, 2023:53-68. doi: 10.1007/978-981-97-9194-1_5
  8. Shcherbatova O., Grebennikov D., Sazonov I., Meyerhans A., Bocharov G. Modeling of the HIV-1 life cycle in productively infected cells to predict novel therapeutic targets. Pathogens. 2020;9(4). Article No. 255. doi: 10.3390/pathogens9040255
  9. Yin J., Redovich J. Kinetic modeling of virus growth in cells. Microbiol. Mol. Biol. Rev. 2018;82(2). Article No. 00066-17. doi: 10.1128/MMBR.00066-17
  10. Chakraborty A., Sun G.Q., Mustavich L., Huang S.H., Li B.L. Biochemical interactions between HIV-1 integrase and reverse transcriptase. FEBS Lett. 2013;587(5):425-429. doi: 10.1016/j.febslet.2012.12.007
  11. Rouzioux C., Hubert J.-B., Burgard M., Deveau C., Goujard C., Bary M., Séréni D., Viard J.-P., Delfraissy J.-F., Meyer L. Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. J. Infect. Dis. 2005;192(1):46-55. doi: 10.1086/430610
  12. Hu W.-S., Hughes S. H. HIV-1 reverse transcription. Cold Spring Harb. Perspect. Med. 2012;2(10). Article No. a006882. doi: 10.1101/cshperspect.a006882
  13. Delelis O., Carayon K., Saïb A., Deprez E., Mouscadet J.F. Integrase and integration: biochemical activities of HIV-1 integrase. Retrovirology. 2008;5. Article No. 14. doi: 10.1186/1742-4690-5-114
  14. Gu S.-X., Xue P., Ju X.-L., Zhu Y.-Y. Advances in rationally designed dual inhibitors of HIV-1 reverse transcriptase and integrase. Bioorg. Med. Chem. 2016;24(21):5007-5016. doi: 10.1016/j.bmc.2016.09.025
  15. Castro-Gonzalez S., Colomer-Lluch M., Serra-Moreno R. Barriers for HIV cure: the latent reservoir. AIDS Res. Hum. Retroviruses. 2018;34(9):739-759. doi: 10.1089/aid.2018.0118
  16. Guo T., Qiu Z., Kitagawa K., Iwami S., Rong L. Modeling HIV multiple infection. J. Theor. Biol. 2021;509. Article No. 110502. doi: 10.1016/j.jtbi.2020.110502
  17. Deng Q., Guo T., Qiu Z., Chen Y. A mathematical model for HIV dynamics with multiple infections: implications for immune escape. J. Math. Biol. 2024;89. Article No. 6. doi: 10.1007/s00285-024-02104-w
  18. FDA. Highlights of prescribing information of Cabenuva. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212888s000lbl.pdf (accessed 03.07.2025).
  19. Sontag E.D. For differential equations with r parameters, 2r + 1 experiments are enough for identification. J. Nonlinear Sci. 2003;12:553-583. doi: 10.1007/s00332-002-0506-0
  20. Maertens G.N., Engelman A.N., Cherepanov P. Structure and function of retroviral integrase. Nat. Rev. Microbiol. 2022;20(1):20-34. doi: 10.1038/s41579-021-00586-9
  21. van Heuvel Y., Schatz S., Rosengarten J.F., Stitz J. Infectious RNA: human immunodeficiency virus (HIV) biology, therapeutic intervention, and the quest for a vaccine. Toxins. 2022;14(2):138. doi: 10.3390/toxins14020138
  22. Krasnosel'skii M.A. The operator of translation along the trajectories of differential equations. Amer. Math. Soc., 1968. 294 p. (Transl. of Math. Monographs, V. 19).
  23. Heffernan J.M., Smith R.J., Wahl L.M. Perspectives on the basic reproductive ratio. J. R. Soc. Interface. 2005;2(4):281-293. doi: 10.1098/rsif.2005.0042
  24. Hethcote H.W. The mathematics of infectious diseases. SIAM Rev. 2000;42(4):599-653. doi: 10.1137/S0036144500371907
  25. Ghosh S., Roy A.K., Roy P.K. Implementation of suitable optimal control strategy through introspection of different delay induced mathematical models for leprosy: A comparative study. Optim. Control Appl. Methods. 2024;45(1):336-361. doi: 10.1002/oca.3060
  26. Ghosh S., Chatterjee A., Roy P., Grigorenko N., Khailov E., Grigorieva E. Mathematical modeling and control of the cell dynamics in leprosy. Computational Mathematics and Modeling. 2021;32:52-74. doi: 10.1007/s10598-021-09516-z
  27. Cao X., Ghosh T., Ghosh S. Mathematical modelling to exhibit the influence of latently infected schwann cells in leprosy: An optimal control-based study. In: International Conference on Mathematical Analysis and Application in Modeling. Springer, 2023:123-137. doi: 10.1007/978-981-97-9194-1_9
  28. Miron R.E., Smith R.J. Modelling imperfect adherence to HIV induction therapy. BMC Infectious Diseases. 2010;10(1):1-16. doi: 10.1186/1471-2334-10-6
  29. Smith R.J., Aggarwala B.D. Can the viral reservoir of latently infected CD4+ T cells be eradicated with antiretroviral HIV drugs? Journal of Mathematical Biology. 2009;59(5):697-715. doi: 10.1007/s00285-008-0245-4
  30. Abiodun G.J., Marcus N., Okosun K.O., Witbooi P.J. A model for control of HIV/AIDS with parental care. International Journal of Biomathematics. 2013;6(02). Article No. 1350006. doi: 10.1142/S179352451350006X
  31. Cunha R.F., Simões S., Carvalheiro M., Pereira J.M.A., Costa Q., Ascenso A. Novel antiretroviral therapeutic strategies for HIV. Molecules. 2021;26(17). Article No. 5305. doi: 10.3390/molecules26175305
  32. Vocabria for the treatment of HIV-1 infection. FDA. https://www.fda.gov/drugs/human-immunodeficiency-virus-hiv/fda-approves-cabenuva-and-vocabria-treatment-hiv-1-infection (accessed 03.07.2025).
  33. Overton E.T., Richmond G., Rizzardini G., Jaeger H., Orrell C., Nagimova F., Bredeek F., Deltoro M.G., Swindells S., Andrade-Villanueva J.F., et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. The Lancet. 2020;396(10267):1994-2005. doi: 10.1016/S0140-6736(20)32666-0
  34. Cutrell A.G., Schapiro J.M., Perno C.F., Kuritzkes D.R., Quercia R., Patel P., Polli J.W., Dorey D., Wang Y., Wu S., Van Eygen V., Crauwels H., Ford S.L., et al. Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis. AIDS. 2021;35(9):1333-1342. doi: 10.1097/QAD.0000000000002883
  35. Wood B.R., Kassaye S.G., Gerstoft J. Long-acting cabotegravir/rilpivirine for HIV-1 treatment: real-world evaluation of barriers to implementation. AIDS. 2023;37(4):689-691. doi: 10.1097/QAD.0000000000003476
  36. Thoueille P., Saldanha S.A., Schaller F., Choong E., Munting A., Cavassini M., Braun D., Günthard H.F., Kusejko K., Surial B., Furrer H., Rauch A., Rougemont M., et al. Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland. The Lancet Regional Health-Europe. 2024;36. doi: 10.1016/j.lanepe.2023.100793
  37. Jaeger H., Overton E.T., Richmond G., Rizzardini G., Andrade-Villanueva J.F., Mngqibisa R., Hermida A.O., Thalme A., Belonosova E., Ajana F., Benn P.D., Wang Y., Hudson K.J., et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. The Lancet HIV. 2021;8(11):e679-e689. doi: 10.1016/S2352-3018(21)00185-5
  38. Orkin C., Schapiro J.M., Perno C.F., Kuritzkes D.R., Patel P., DeMoor R., Dorey D., Wang Y., Han K., Van Eygen V., et al. Expanded multivariable models to assist patient selection for long-acting cabotegravir+ rilpivirine treatment: clinical utility of a combination of patient, drug concentration, and viral factors associated with virologic failure. Clinical Infectious Diseases. 2023;77(10):1423-1431. doi: 10.1093/cid/ciad370
  39. Thoueille P., Choong E., Cavassini M., Buclin T., Decosterd L.A. Long-acting antiretrovirals: a new era for the management and prevention of HIV infection. Journal of Antimicrobial Chemotherapy. 2022;77(2):290-302. doi: 10.1093/jac/dkab324
Содержание
Оригинальная статья
Tushar Ghosh, Priti Kumar Roy Critical Analysis of FDA-Approved Dual Inhibitor Cabenuva to HIV Replication Kinetics: A Mathematical Study. Маthematical biology and bioinformatics. 2025;20(2):236-268. doi: 10.17537/2025.20.236
(опубликована на англ. яз.)

Аннотация (англ.)
Аннотация (рус.)
Полный текст (англ., pdf)
Список литературы

 
  Copyright ИМПБ РАН © 2005-2026